Open Access | Mini Review
This work is licensed under a Creative
Commons Attribution-ShareAlike 4.0 International License.
Sotrovimab for treatment of COVID-19 infections
* Corresponding author: Shyh Poh Teo
Mailing address: Department of Internal Medicine, RIPAS Hospital, Bandar Seri Begawan, BA 1710, Brunei Darussalam.
Email: shyhpoh.teo@moh.gov.bn
Received: 28 April 2022 / Revised: 09 June 2022 / Accepted: 17 June 2022 / Published: 30 June 2022
DOI: 10.31491/APT.2022.06.087
Abstract
The COVID-19 pandemic necessitates the development of therapeutic agents for high-risk infected patients. Sotrovimab is a monoclonal antibody with efficacy against SARS-CoV-2 and other sarbecoviruses. Its efficacy has been shown in the COMET-ICE trial, where a 500 mg infusion in non-hospitalized patients with mild to moderate COVID-19 infections and at least one risk factor for progression was associated with reduced disease progression, hospitalization and death. There was a small but statistically significant increase in self-limiting diarrhoea with sotrovimab. For hospitalized patients, there is no strong evidence of benefit with sotrovimab. The emergence of the Omicron variant was associated with reduced efficacy of sotrovimab, with subsequent increased resistance to sotrovimab by the BA.2 sub-lineage. The risk of developing resistance to monoclonal antibodies with increased use, efficacy with the emergence of variants and safety monitoring should continue to provide ongoing risk-benefit analysis of their use.
Keywords
COVID-19, monoclonal antibodies, therapeutics
Introduction
The COVID-19 pandemic has significant implications for
the health of older people, ranging from the higher risk of
COVID-19 infection related complications and mortality,
to the morbidity from delays in seeking medical attention
and mental health sequalae [1]. COVID-19 vaccines have
been rolled out globally to reduce the risk of infections,
hospitalisations or death. This has been shown to be effective
in high-risk groups, particularly older people and
those with underlying medical conditions, such as diabetes
mellitus, chronic obstructive pulmonary disease, chronic
renal disease and obesity [2].
In addition to preventive measures such as vaccination,
social isolation, use of masks and hand hygiene measures,
therapeutic agents are required especially for highrisk
patients infected with the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). This includes
monoclonal antibodies (mAbs), which ideally bind to the
SARS-CoV-2 virus in a region separate to the frequently
evolving receptor-binding motif. In this paper, the mAb,Sotrovimab, and relevant papers pertaining to its efficacy
in COVID-19 infections and safety are described.
Efficacy and safety of sotrovimab
MAbs were previously isolated from the SARS-CoV-1
virus, which caused the SARS outbreak approximately
twenty years ago. Subsequently, sotrovimab (VIR-7831)
was developed as an engineered human mAb that has the
ability to neutralize SARS-CoV-2 and other sarbecoviruses.
It has two-amino acid Fc modifications to prolong its
half-life and to improve bioavailability in the respiratory
mucosa. Unlike several other mAbs developed against
COVID-19, sotrovimab does not depend on binding to the
angiotensin-converting enzyme 2 (ACE2) receptor, which
is prone to mutations [3].
A phase 3, double-blind, placebo-controlled trial (COMET-ICE)
was performed in multiple centres in the United
States, Canada, Brazil and Spain, to evaluate the effects of
a single dose of sotrovimab 500 mg infusion in preventing
progression of COVID-19 infection severity in high-risk,
non-hospitalised patients. Patients included in the trial had
confirmed COVID-19 infections on reverse-transcriptase
polymerase-chain-reaction or antigen SARS-CoV-2 testing,
had symptom onset within five days and were considered
high-risk of hospitalisation or death from the infection
due to at least one risk factor or older age. Patients
with severe COVID-19 infections evidenced by dyspnoea
at rest, hypoxia or requiring supplemental oxygen were
excluded from the study.
In a pre-specified interim analysis based on an intentionto-treat
sample of 583 patients (291 with sotrovimab, 292
with placebo), there were 3 patients (1%) and 21 (7%)
who progressively worsened, leading to hospitalization
and death in the sotrovimab and placebo groups respectively.
This was a relative risk reduction of 85%, which
was statistically significant. Five patients were admitted to
intensive care, all of whom were from the placebo group.
In terms of safety, 17% and 19% reported adverse events
in the sotrovimab and placebo groups respectively. For the
sotrovimab group, the most common adverse event was
diarrhoea, occuring in 1%. One patient in the sotrovimab
group developed an infusion-related reaction, with symptoms
of moderate dyspnoea. Based on the interim analysis
of the COMET-ICE trial, sotrovimab appeared safe and
effective in reducing the risk of disease progression for
outpatient mild to moderate COVID-19 patients who are
considered high risk [3].
By the time the COMET-ICE study was completed, patient
recruitment had extended to 57 sites, with the addition
of Peru to the list of countries [4]. However, enrollment
was stopped earlier at a prespecified interim analysis
due to efficacy. There were 1057 randomly selected patients,
with one-fifth being 65 years of age and older and
more than half being Latinx. The sotrovimab group was
associated with a significant reduction of all-cause hospitalization
and death compared to placebo (1% vs 6%, relative
risk 0.21, absolute difference -4.91%, number needed
to treat 20.4). In terms of safety, while there were more
adverse events in the placebo group, self-limiting diarrhoea
was reported by more patients receiving sotrovimab
(2%) compared to placebo (< 1%). There was no significant
difference between groups for systemic infusion-related
reactions. Overall, the COMET-ICE study supported
sotrovimab as a treatment for high-risk outpatients with
mild to moderate COVID-19 infections [4].
In a retrospective study from Obaidullah Hospital, United
Arab Emirates, 220 patients who received Sotrovimab
were monitored in terms of progression to severe disease.
Among these patients, 177 (80.5%) improved, while
43 (19.5%) deteriorated in terms of shortness of breath,
cough and worsening of radiological findings on chest
x-ray. The rate of hospitalization was 18.6% with sotrovimab.
However, there was overall statistically significant
improvement after sotrovimab in terms of vital signs, inflammatory
markers, hepatic and renal functions [5].
An observational cross-sectional study was carried out in
the National Centre for Infectious Diseases (NCID), the
largest COVID-19 treatment centre in Singapore. Out of
410 COVID-19 inpatients, 94 met the inclusion criteria
of confirmed COVID-19 admitted within five days, not
requiring oxygen and did not receive full doses of COVID-19
vaccination. Among these patients, 19 (20.2%)
received pre-emptive sotrovimab treatment. Although
the sotrovimab group was significantly older (mean age
73 years) and had more comorbidities, there were less
patients who progressed to requiring oxygen (31.6% vs
54.7%), admission to intensive care (10.5% vs 24.0%) or
death (5.3% vs 13.3%). This suggested that sotrovimab may be useful for early treatment of high-risk inpatients
with mild-to-moderate COVID-19 infections [6].
However, this was not demonstrated in a randomizedcontrolled
trial comparing the efficacy of sotrovimab and
BRII-196 plus BRII-198 (amubarvimab/romlusevimab).
This was a multi-centred study performed across 43 hospitals
in the United States, Denmark, Switzerland and
Poland. There were 546 patients who were admitted with
moderate to severe COVID-19 infections without organ
failure and presented with symptoms for less than 12 days.
They were administered a single dose of the study product
over 60 minutes, and monitored for infection complications,
organ failure, co-infections and death. However,
an interim futility analysis showed that there was no improvement
in clinical outcomes for sotrovimab or BRII196
plus BRII-198 in this group of patients, resulting in
the study being terminated early [7]. This may be contributed
by the extended length of time before receiving the
infusion.
Overall, the available evidence suggests that sotrovimab
is useful for outpatient use for patients presenting within
5 days of symptoms with mild-moderate COVID-19
infections who are considered high risk of developing
complications. Its use for inpatients or those with severe
COVID-19 infections currently remains unproven.
Efficacy of sotrovimab in COVID-19 variants
The effectiveness of mAbs, including casirivimab, imdevimab
and sotrovimab has been confirmed for the Delta
variant [8]. An observational study from the University
of Pittsburgh School of Medicine showed that the 3558
patients who received the mAb infusions at an outpatient
center had a reduced risk of hospitalization or death compared
to those without treatment. There was a relative risk
reduction of 0.31 and 0.60 for casirivimab/imdevimab and
sotrovimab respectively. Although there was no statistically
significant difference in the effectiveness of both mAbs,
there was an 86% probability of inferiority of sotrovimab
compared to casirivimab/imdevimab against the Delta
variant [8].
Currently, the main SARS-CoV-2 variant is Omicron
(B.1.1.529) with multiple mutations (37 amino acid substitutions)
in the spike protein, including 15 in the receptorbinding
domain (RBD). This was associated with a loss of
in-vitro neutralizing activity against Omicron for 26 out of
29 mAbs which target the RBD motif, leaving three mAbs
with retained potency. For the broadly neutralizing sarbecovirus
mAbs, sotrovimab, in addition to S2X259 and
S2H97 retained their potency [9]. In another study, pooled
human IgG from convalescent and vaccinated donors
had a reduced potency of 16-fold with the variant, while
among the therapeutic mAbs tested, only sotrovimab resulted
in significant neutralization of Omicron [10].
These findings were replicated in two other in-vitro studies.
The first assessed nine mAbs and 115 serum samples
from recovered patients or vaccine recipients. This study
found that serum from Pfizer or AstraZeneca vaccine recipients, or those with previous infections at least 6
months prior, had low or no neutralizing activity against
Omicron. Serum from recipients of Pfizer booster doses
elicited a response, but at titres 6 to 23-fold lower compared
to against the Delta variant [11]. The second study
found that over 85% of their tested neutralizing mAbs
had limited efficacy, including LY-CoV016, LY-CoV555,
REGN10933, REGN10987, AZD1061, AZD8895 and
BRII-196. However, VIR-7831 and DXP-604 had some
efficacy, albeit a reduced one [12].
Subsequently, a report demonstrating the presence and
persistence of viable Omicron SARS-CoV-2 virus despite
treatment with sotrovimab suggested the possibility of
development of resistance against mAbs due to the rapid
development of mutations on the spike protein [13]. The
Erasmus University Medical Centre in Rotterdam assessed
viral evolution in immunocompromised patients
(from solid organ transplant or previous B-cell depleting
therapy) infected by Omicron BA.1 or 2 and treated with
sotrovimab. Four patients had viral RNA detected for a
longer duration, up to 28 days. These patients had spike
protein mutations at position 337 or 340, with an associated
reduction in susceptibility [14]. This development of
treatment resistant SARS-CoV-2 variants was also identified
in a similar study from Toulouse University Hospital
[15]. Thus, consideration should be given to ensure
confirmed viral clearance after treatment to avoid these
patients becoming a source of new variants. This also suggests
the need for mAb stewardship and raised concerns
regarding future treatment failure with ongoing mAbs use.
The Omicron BA.1 variant is being replaced by the BA.2
sub-lineage with different spike protein mutations, with a
gain of 8 new and loss of 13 spike alterations compared
to BA.1. A further reduction in neutralizing efficacy of
Sotrovimab by 50% with BA.2 was initially suggested
[16]. Since then, further testing showed the BA.2 variant
developed significant resistance to 17 of 19 neutralising
monoclonal antibodies, including sotrovimab [17]. This
highlighted the necessity of active, ongoing monitoring of
mAB efficacy and amending treatment options accordingly
based on the main variant causing SARS-CoV-2 infections.
For the BA.2 sublineage, this includes use of bebtelovimab
(LY-CoV1404) [17], or considering combination
therapy with sotrovimab to ensure a broader spectrum of
cover [18].
Overall, during the Delta pandemic, mAbs generally held
significant promise in neutralizing the SARS-CoV-2 virus.
Casirivimab/imdevimab which was potentially more
effective than sotrovimab at that time has been rendered
useless by the Omicron variant; while sotrovimab retained
some efficacy against BA.1 [19]. However, there is increasing
resistance through rapid mutations by the SARSCoV-2
virus with a further reduction in efficacy against
the BA.2 sub-lineage. Eventually, the United States Food
and Drug Administration (FDA) limited the use of sotrovimab
in areas where Omicron BA.2 variant contributed
to more than half the COVID-19 cases on March 30th,
2022, with a subsequent withdrawal of their authorization
to use sotrovimab on April 5th, 2022, when the BA.2 variant
became the main cause of COVID-19 infections in all regions in the United States [20].
Safety monitoring of sotrovimab
In addition to monitoring for ongoing efficacy against
COVID-19 variants, safety monitoring is also required.
Pharmacovigilance for adverse events should be considered,
rather than symptoms assumed to be due to the
progression of COVID-19. This was illustrated in a case
of a patient who developed alveolar haemorrhage postinfusion,
which was initially thought to be due to COVIDassociated
pneumonia [21]. The long-term sequalae of
monoclonal antibody use, particularly effects on the immune
system should also be monitored.
As all therapeutics can potentially result in side effects,
there is a view that it may no longer be appropriate to
carry out studies for mABs in hospitalized COVID-19
patients [22]. Other than severe immunocompromised
patients where studies may be appropriate, the lack of efficacy
for hospitalized patients with moderate to severe
COVID-19 infections has already been demonstrated in
multiple mAb studies [22].
Conclusion
Sotrovimab is a mAb with demonstrable efficacy in reducing the risk of progression to hospitalization, clinical deterioration and death for high-risk outpatients with mild to moderate COVID-19 infections. However, it has not been found to be effective for inpatient treatment, and is gradually becoming less effective with the development of COVID-19 variants, including Omicron and the BA.2 sub-lineage. Subsequently, the FDA withdrew emergency use authorization of Sotrovimab when the Omicron BA.2 variant eventually became the main cause of COVID-19 infections in the United States.
Declarations
Authors’ contributions
The author contributed solely to the article.
Availability of data and materials
Not applicable.
Financial support and sponsorship
None.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval and informed consent
Not applicable.
Consent for publication
Not applicable.
References
1. Sofian AIH, Md Jappar SAN, Amzizulfadzillah AF, Mat Sarudin MSH, Husaini NH, Yaakub A, et al. COVID-19 pandemic situation analysis for Brunei Darussalam - perspectives from the front line, geriatric medicine and mental health. Pac J Med Sci, 2021, 21(2): 5-11.
2. Teo SP. Review of COVID-19 vaccines and their evidence in older people. Ann Geriatr Med Res, 2021, 25(1): 4-9. [Crossref]
3. Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARSCoV-2 neutralizing antibody sotrovimab. N Engl J Med, 2021, 385: 1941-1950. [Crossref]
4. Gupta A, Gonzalez-Rojas Y, Juarez E, Casal MC, Moya J, Falci DR, et al. Effect of Sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19. JAMA, 2022, 327(13): 1236-1246. [Crossref]
5. Elesdoudy A. Sotrovimab: is it effective in early treatment of mild and moderate COVID-19 infections? A retrospective study. Egypt J Bronchol, 2021, 15: 56. [Crossref]
6. Ong SWX, Ren D, Lee PH, Sutjipto S, Dugan C, Knoo BY, et al. Real-world use of sotrovimab for pre-emptive treatment in high-risk hospitalized COVID-19 patients: an observational cross-sectional study. Antibiotics, 2022, 11(3): 345. [Crossref]
7. Self WH, Sandkovsky U, Reilly CS, Vock DM, Gottlieb RL, Mack M, et al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis, 2021, 22(5): 622-635. [Crossref]
8. Huang DT, McCreary EK, Bariola R, Minnier TE, Wadas RJ, Shovel JA, et al. Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial. medRxiv [Preprint]. 2021 medRxiv [posted 2021 December 27]. Available from: https:// www.medrxiv.org/content/10.1101/2021.12.23.21268 244v1. [Crossref]
9. Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al. Broadly neutralizing antibodies overcome SARSCoV-2 Omicron antigenic shift. Nature, 2022, 602: 664- 670. [Crossref]
10. Aggarwal A, Stella AO, Walker G, Akerman A, Milogiannakis V, Brilot F, et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv [Preprint]. 2021 medRxiv [posted 2021 December 15]. Available from: https://www.medrxiv.org/conte nt/10.1101/2021.12.14.21267772v1. [Crossref]
11. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchias C, Buchrieser J, et al. Considerable escape of SARS_ CoV-2 Omicron to antibody neutralization. Nature, 2022, 602: 671-675. [Crossref]
12. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature, 2022, 602: 657-663. [Crossref]
13. Rockett RJ, Basile K, Maddocks S, Aguis JE, Arnott A,Chandra S, et al. Resistance mutations in SARS-CoV-2 delta variant after Sotrovimab use. N Engl J Med, 2022, 386(15): 1477-1479. [Crossref]
14. Huygens S, Munnink BO, Gharbharan A, Koopmans M, & Rijnders B. High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant. medRxiv [Preprint]. 2022 medRxiv [posted 2022 April 06]. Available from: https://www.medrxiv.org/con tent/10.1101/2022.04.06.22273503v1. [Crossref]
15. Velas C, Tremeaux P, Del Bello AD, Latour J, Jeanne N, Ranger N, et al. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clin Microbiol Infect, 2022, S1198-743X(22)00258-0. [Crossref]
16. Touret F, Baronti C, Pastorino B, Villarroel PMS, Ninove L, Nougairede A, et al. In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1 and BA.2. Research Square [Preprint]. 2022 Research Square [posted 2022 March 08]. Available from: https://www.researchsquare.com/article/rs-1415749/v1. [Crossref]
17. Iketani S, Liu L, Guo Y, Liu L, Chan JFW, Huang Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 2022, 604: 553-556. [Crossref]
18. Passariello M, Ferrucci V, Sasso E, Manna L, Lembo RR, Pascarella S, et al. A novel human neutralizing mAb recognizes delta, gamma and omicron variants of SARSCoV-2 and can be used in combination with sotrovimab. Int J Mol Sci, 2022, 23(10): 5556. [Crossref]
19. Mader AL, Tydykov L, Gluck V, Bertok M, Weidlich T, Gottwald C, et al. Omicron’s binding to Sotrovimab, Casirivimab, Imdevimab, CR3022, and sera from previously infected or vaccinated individuals. iScience, 2022, 25(4): 104076. [Crossref]
20. United States Food & Drug Administration. FDA updates Sotrovimab emergency use authorization. [Internet]. United States: USFDA; 2022 [updated 2022 Apr 5, cited 2022 Jun 16]. Available from: https://www.fda.gov/ drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization. [Crossref]
21. Evangelou K, Rozani S, & Tsagkaris C. Monoclonal antibodies as a trick or treat for COVID-19? The example of abciximab. J Med Virol, 2022, 94(5): 1794-1795. [Crossref]
22. Shapiro AE, Ignacio RAB. Time to knock monoclonal antibodies off the platform for patients hospitalized with COVID-19. Lancet Infect Dis, 2021, 22(5): 567-569. [Crossref]